The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
Open accessAbstract
Development of improved RNA interference–based strategies is of utmost clinical importance. Although siRNA-mediated silencing of EphA2, an ovarian cancer oncogene, results in reduction of tumor growth, we present evidence that additional inhibition of EphA2 by a microRNA (miRNA) further “boosts” its antitumor effects. We identified miR-520d-3p as a tumor suppressor upstream of EphA2, whose expression correlated with favorable outcomes in two independent patient cohorts comprising 647 patients. Restoration of miR-520d-3p prominently decreased EphA2 protein levels, and suppressed tumor growth and migration/invasion both in vitro and in vivo. Dual inhibition of EphA2 in vivo using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes loaded with miR-520d-3p and EphA2 siRNA showed synergistic antitumor efficiency and greater therapeutic efficacy than either monotherapy alone. This synergy is at least in part due to miR-520d-3p targeting EphB2, another Eph receptor. Our data emphasize the feasibility of combined miRNA–siRNA therapy, and will have broad implications for innovative gene silencing therapies for cancer and other diseases. Significance: This study addresses a new concept of RNA inhibition therapy by combining miRNA and siRNA in nanoliposomal particles to target oncogenic pathways altered in ovarian cancer. Combined targeting of the Eph pathway using EphA2-targeting siRNA and the tumor suppressor miR-520d-3p exhibits remarkable therapeutic synergy and enhanced tumor suppression in vitro and in vivo compared with either monotherapy alone. Cancer Discov; 3(11); 1302–15. ©2013 AACR. See related commentary by Kasinski and Slack, p. 1220 This article is highlighted in the In This Issue feature, p. 1207
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Cited by
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Self-citationEmerging Frontiers in Drug Delivery
Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 975
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Self-citation
Metadata
- Authors
- Nishimura, M., Jung, E.-J., Shah, M. Y., Lu, C., Spizzo, R., Shimizu, M., Han, H. D., Ivan, C., Rossi, S., Zhang, X., Nicoloso, M. S., Wu, S. Y., Almeida, M. I., Bottsford-Miller, J., Pecot, C. V., Zand, B., Matsuo, K., Shahzad, M. M., Jennings, N. B., Rodriguez-Aguayo, C., Lopez-Berestein, G., Sood, A. K., & Calin, G. A.
- Venue
- Cancer Discovery
- Published
- 2013-11-01
- Volume
- 3
- Issue
- 11
- Pages
- 1302-1315
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2139242035
- Cited by
- 160
- References
- 1
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0159
- The paper
- Nishimura, M., Jung, E.-J., Shah, M. Y., Lu, C., Spizzo, R., Shimizu, M., Han, H. D., Ivan, C., Rossi, S., Zhang, X., Nicoloso, M. S., Wu, S. Y., Almeida, M. I., Bottsford-Miller, J., Pecot, C. V., Zand, B., Matsuo, K., Shahzad, M. M., Jennings, N. B., . . . Calin, G. A. (2013). Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.